Metagenomi Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
MGX$0.70-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue | $1,248 | $4,127 |
| Operating expenses: | ||
| Research and development | 19,300 | 25,142 |
| General and administrative | 6,535 | 6,805 |
| Total operating expenses | 25,835 | 31,947 |
| Loss from operations | (24,587) | (27,820) |
| Other income (expense): | ||
| Interest income | 1,539 | 2,887 |
| Other expense, net | (1) | (8) |
| Total other income, net | 1,538 | 2,879 |
| Net loss before provision for income taxes | (23,049) | (24,941) |
| Provision for income taxes | (10) | (98) |
| Net loss | $(23,059) | $(25,039) |
| Other comprehensive income (loss): | ||
| Unrealized loss on available-for-sale marketable securities | (304) | (88) |
| Comprehensive loss | $(23,363) | $(25,127) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.61) | $(0.68) |
| Weighted average common shares outstanding, basic and diluted | 37,581,094 | 37,019,027 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.